Figure 6

Efficient depletion of B22a1⁺ T cells before arthritis onset has limited effect on clinical disease. (a) The indicated numbers of Vβ12-transgenic male mice were treated with B22a1 and MAR18.5 antibodies 4 hours prior to immunization with collagen type II (CII) and followed for development of arthritis. (b) Frequencies of B22a1⁺ T cells by the end of the arthritis experiment were assessed by flow cytometry in the lymph nodes and spleen. (c) Anti-CII IgG antibody levels at days 17 and 35 after immunization are shown as box plots. (d) Scatter plot showing the frequencies of CD4⁺ T cells being B22a1^- and B22a1⁺ and expressing CD40L after 6 hours of restimulation in the presence of the GalHyK264 peptide and Brefeldin A by the end of the arthritis experiment at day 35. *P < 0.05, **P < 0.01, ***P < 0.001.